Form 4: Integra LifeSciences CEO Reports RSU Vesting & Tax Sales

Integra LifeSciences CEO Mojdeh Poul reported the vesting of restricted stock units and subsequent tax-related dispositions.

Summary

• Mojdeh Poul, President & CEO and Director of Integra LifeSciences Holdings Corp (IART), reported transactions on January 6, 2026, related to restricted stock units (RSUs).
• A total of 1,390 shares of common stock vested from RSU awards (comprising 848 shares and 542 shares) at an exercise price of $0.
• Concurrently, 1,390 shares of common stock were disposed of at a price of $13.13 per share to cover tax withholding obligations associated with the RSU vesting.
• The net effect of these specific transactions on direct beneficial ownership of common stock is zero.
• Following these transactions, Mojdeh Poul beneficially owns 102,840 and 102,298 restricted stock units, representing future potential common stock.

Sentiment

Score: 5

Explanation: The filing details routine executive compensation transactions (RSU vesting and tax withholding) and does not contain information that would alter the fundamental investment thesis for Integra LifeSciences Holdings Corp. These are pre-scheduled events and do not reflect new operational or strategic developments.

Positives

• The vesting of restricted stock units represents a component of executive compensation, aligning management's interests with shareholder value over the long term.

Negatives

• The disposition of shares for tax withholding purposes is a routine event and not indicative of a negative outlook for the company.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This filing is a routine disclosure of executive compensation and does not provide insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The filing reflects routine executive compensation practices, which are part of the company's overall governance and compensation structure.
• Employees, Customers, Suppliers, Creditors: No direct or significant impact is indicated by this routine insider transaction report.

Next Steps

• The remaining installments of the restricted stock unit award are scheduled to vest on the second and third anniversaries of the grant date of January 6, 2025.
• Shares from vested RSUs will be delivered to Ms. Poul within 30 days following the first business day that occurs immediately following the six-month period after her separation of service, as deferred compensation.

Key Dates

Recommendation

The filing details routine executive compensation transactions (RSU vesting and tax withholding) and does not contain information that would alter the fundamental investment thesis for Integra LifeSciences Holdings Corp. These are pre-scheduled events and do not reflect new operational or strategic developments, thus a 'hold' recommendation is appropriate as no new material information for a buy or sell decision is presented.

Keywords

Integra LifeSciences, IART, Form 4, Insider Transaction, Stock Vesting, Restricted Stock Units, Executive Compensation